-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA CLEARS MOTIVISTA (CT-155), THE FIRST AUTHORIZED TREATMENT FOR NEGATIVE SCHIZOPHRENIA SYMPTOMS

Reuters·10/05/2026 19:15:32

Please log in to view news